Mukka Proteins Faces Sales Decline Amid Adjusted Market Evaluation and Growth Potential
Mukka Proteins, a small-cap aquaculture company, has recently adjusted its evaluation amid challenges in quarterly performance, including a notable decline in net sales and profit after tax. Despite these difficulties, the company shows long-term growth potential, with historical sales growth and a solid return on capital employed.
Mukka Proteins, a small-cap player in the aquaculture industry, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the technical landscape surrounding the stock, indicating a transition from a bearish outlook to a mildly bearish stance. Key financial metrics reveal that Mukka Proteins has faced challenges in its recent quarterly performance, with net sales showing a significant decline. The company reported net sales of Rs 452.35 crore, reflecting a contraction of 46.71%. Additionally, the profit after tax (PAT) for the same period was Rs 28.34 crore, down by 26.85%.
Despite these hurdles, there are indications of long-term growth potential, as net sales have historically grown at an annual rate of 35.30%, and operating profit has surged by 96.45%. The stock's return on capital employed (ROCE) stands at 7.8, suggesting a fair valuation relative to its enterprise value.
Overall, Mukka Proteins continues to navigate a complex market environment, with its recent evaluation adjustment highlighting the evolving technical trends and underlying financial metrics.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
